Merck Says Zepatier Yields High HCV Cure Rates in US Veterans Study
Veterans had undetectable HCV RNA 12 weeks after treatment with the DAA.
Read More
WHO Prequalifies First Generic Ingredient for Hepatitis C Medicines
For the first time, the WHO has prequalified a generic API for treating HCV.
Hepatitis B, C Threat Can Be Eliminated in the US by 2030, Physicians Say
Aggressive testing, treatment, and prevention methods are key.
Gilead's Hepatitis C Drug Patent Challenged by 30 Groups Across Europe
A 12-week hepatitis C regimen costs $59,000 in Europe.
Insurers Deny Coverage After Physicians Prescribe Hepatitis C Treatment
Effective hepatitis C drugs continue to be withheld from patients.
Liver Inflammation Lingers in Some Patients After Hepatitis C Is Eradicated
Even patients with cured hepatitis C from DAAs exhibited liver inflammation.
Egypt Promotes Medical Tourism for Hepatitis C Treatment
See the pyramids, get hepatitis C treatment? Egypt promotes medical tourism.
Merck Takes Major Write-Down on Hepatitis C Drug
Merck acquired uprifosbuvir after purchasing Idenix Pharmaceuticals Inc. for $3.85 billion.